… Treatment with nab-paclitaxel versus dacarbazine resulted in a significant improvement in …
The results observed for dacarbazine in this study were consistent with recent phase III trials [3…

… This study was designed to compare the overall survival time, rate of … dacarbazine treatment
in stage IV melanoma patients. PATIENTS AND METHODS: In this multicenter phase III trial, …

… treatment group but had not been reached at the conclusion of the study for the
temozolomide treatment … in the temozolomide treatment group; 18 of the 21 temozolomide-treatment …

… our study started in 2006, new treatments have been approved for MM 35 . In phase III … to
improve the survival of MM patients treated previously with chemotherapy and whose disease …

… Because these were nonrandomized studies, we conducted a milestone survival analysis of
data from a randomized, controlled phase III trial to confirm the survival benefit of ipilimumab …

… this study with DBDT did not meet our requirements to consider this regimen appropriate for
a phase III study… alone in our study could be due to the characteristics of the treated patients (…

… with dacarbazine was found the treatment with the highest response rate in our series. These
findings are consistent with previous studies … of OS compared with dacarbazine alone. In a …

… The aim of the study was to detect a difference between the two treatment arms in terms of
overall survival rate at 2 years. The goal was set initially to enter 156 patients to detect a 15% …

… , randomized phase III trials of sorafenib and dacarbazine in the treatment of advanced
melanoma are warranted to unequivocally establish the benefit of this treatment combination. …

… dacarbazine but within the CIs for our sample size. The majority of the patient population
studied … of only 12% for patients treated with dacarbazine, despite a predominance of patients …